Skip to main content
Top
Published in: Annals of Surgical Oncology 9/2008

01-09-2008 | Endocrine Tumors

Treatment Outcomes in Anaplastic Thyroid Carcinoma: Survival Improvement in Young Patients With Localized Disease Treated by Combination of Surgery and Radiotherapy

Authors: Thomas Yau, MBBS, C. Y. Lo, MS, R. J. Epstein, MD, A. K. Y. Lam, MD, PhD, K. Y. Wan, MBBS, Brian H. Lang, MS

Published in: Annals of Surgical Oncology | Issue 9/2008

Login to get access

Abstract

Background

Anaplastic thyroid carcinoma (ATC) is a notoriously aggressive malignancy associated with a highly lethal clinical course despite therapeutic intervention. Our present study attempts to identify factors that could potentially improve therapeutic strategies by analyzing the clinicopathological features, treatment and outcome of ATC patients managed over the past four decades at our institution.

Methods

Fifty patients with biopsy-proven ATC during the period 1966 to 2006 were studied. All patients were managed with surgery, radiotherapy, chemotherapy and/or chemoradiation. Survival was calculated by the Kaplan-Meier method. Potential factors affecting survival were compared by the log rank test.

Results

Most patients (88%) presented with a neck mass; 17 patients (34%) also had cervical lymphadenopathy. Distant metastases were clinically present in 9 (18%). Median survival was 97 days, whereas the 1- and 3-year survival was 14% and 8%, respectively. On univariate analysis, patients aged ≤65 years (P = .04), absence of metastatic disease at presentation (P < .01), surgical resection (P < .01), and postoperative radiotherapy (P < .01) were associated with longer survival. The adoption of cytotoxic chemotherapy was not associated with better survival (P = .4). Moreover, there was no improvement in survival rate over the last four decades despite the adoption of multimodal treatment (P = .5).

Conclusion

ATC remains a deadly disease despite technical advances in surgical technique and adoption of multidisciplinary treatment strategies over the last four decades. However, younger patients with localized ATC might benefit from an aggressive multidisciplinary approach.
Literature
1.
go back to reference Hundahl SA, Fleming ID, Fremgen AM et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer 1998;83:2638–48PubMedCrossRef Hundahl SA, Fleming ID, Fremgen AM et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer 1998;83:2638–48PubMedCrossRef
2.
go back to reference Kitamura Y, Shimizu K, Nagahama M et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 1999;84:4043–9PubMedCrossRef Kitamura Y, Shimizu K, Nagahama M et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 1999;84:4043–9PubMedCrossRef
3.
go back to reference Aldinger KA, Samaan NA, Ibanez M et al. Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 1978;41:2267–75PubMedCrossRef Aldinger KA, Samaan NA, Ibanez M et al. Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 1978;41:2267–75PubMedCrossRef
4.
go back to reference Demeter JG, De Jong SA, Lawrence AM et al. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 1991;110:956–61PubMed Demeter JG, De Jong SA, Lawrence AM et al. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 1991;110:956–61PubMed
5.
go back to reference Schlumberger M, Parmentier C, Delisle MJ et al. Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 1991;67:564–6PubMedCrossRef Schlumberger M, Parmentier C, Delisle MJ et al. Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 1991;67:564–6PubMedCrossRef
6.
go back to reference Kobayashi T, Asakawa H, Umeshita K et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 1996;18:36–41PubMedCrossRef Kobayashi T, Asakawa H, Umeshita K et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 1996;18:36–41PubMedCrossRef
7.
go back to reference Rosen IB. (1997) Anaplastic carcinoma of the thyroid gland. In Duh QY, Clark OH (eds). Textbook of Endocrine Surgery. Philadelphia: Sauders. 127–32 Rosen IB. (1997) Anaplastic carcinoma of the thyroid gland. In Duh QY, Clark OH (eds). Textbook of Endocrine Surgery. Philadelphia: Sauders. 127–32
8.
go back to reference Goldman JM, Goren EN, Cohen MH et al. Anaplastic thyroid carcinoma: long-term survival after radical surgery. J Surg Oncol 1980;14:389–94PubMedCrossRef Goldman JM, Goren EN, Cohen MH et al. Anaplastic thyroid carcinoma: long-term survival after radical surgery. J Surg Oncol 1980;14:389–94PubMedCrossRef
9.
go back to reference Mitchell G, Huddart R, Harmer C. Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1999;50:33–8PubMedCrossRef Mitchell G, Huddart R, Harmer C. Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1999;50:33–8PubMedCrossRef
10.
go back to reference Simpson WJ. Anaplastic thyroid carcinoma: a new approach. Can J Surg 1980;23:25–7PubMed Simpson WJ. Anaplastic thyroid carcinoma: a new approach. Can J Surg 1980;23:25–7PubMed
11.
go back to reference Kim JH, Leeper RD. Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination Adriamycin and radiation therapy. A new approach. Cancer 1983;52:954–7PubMedCrossRef Kim JH, Leeper RD. Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination Adriamycin and radiation therapy. A new approach. Cancer 1983;52:954–7PubMedCrossRef
12.
go back to reference Tennvall J, Tallroth E, el Hassan A et al. Anaplastic thyroid carcinoma. Doxorubicin, hyperfractionated radiotherapy and surgery. Acta Oncol 1990;29:1025–8PubMedCrossRef Tennvall J, Tallroth E, el Hassan A et al. Anaplastic thyroid carcinoma. Doxorubicin, hyperfractionated radiotherapy and surgery. Acta Oncol 1990;29:1025–8PubMedCrossRef
13.
go back to reference Voutilainen PE, Multanen M, Haapiainen RK et al. Anaplastic thyroid carcinoma survival. World J Surg 1999;23:975–8PubMedCrossRef Voutilainen PE, Multanen M, Haapiainen RK et al. Anaplastic thyroid carcinoma survival. World J Surg 1999;23:975–8PubMedCrossRef
14.
go back to reference Kebebew E, Greenspan FS, Clark OH et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005;103:1330–5PubMedCrossRef Kebebew E, Greenspan FS, Clark OH et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005;103:1330–5PubMedCrossRef
16.
go back to reference Lang BH, Lo CY. Surgical options in undifferentiated thyroid carcinoma. World J Surg 2007;31:969–77PubMedCrossRef Lang BH, Lo CY. Surgical options in undifferentiated thyroid carcinoma. World J Surg 2007;31:969–77PubMedCrossRef
17.
go back to reference Myskow MW, Krajewski AS, Dewar AE et al. The role of immunoperoxidase techniques on paraffin embedded tissue in determining the histogenesis of undifferentiated thyroid neoplasms. Clin Endocrinol (Oxf) 1986;24:335–41CrossRef Myskow MW, Krajewski AS, Dewar AE et al. The role of immunoperoxidase techniques on paraffin embedded tissue in determining the histogenesis of undifferentiated thyroid neoplasms. Clin Endocrinol (Oxf) 1986;24:335–41CrossRef
18.
go back to reference Tobler A, Maurer R, Hedinger CE. Undifferentiated thyroid tumors of diffuse small cell type. Histological and immunohistochemical evidence for their lymphomatous nature. Virchows Arch A Pathol Anat Histopathol 1984;404:117–26PubMedCrossRef Tobler A, Maurer R, Hedinger CE. Undifferentiated thyroid tumors of diffuse small cell type. Histological and immunohistochemical evidence for their lymphomatous nature. Virchows Arch A Pathol Anat Histopathol 1984;404:117–26PubMedCrossRef
19.
go back to reference Haigh PI, Ituarte PH, Wu HS et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001;91:2335–42PubMedCrossRef Haigh PI, Ituarte PH, Wu HS et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001;91:2335–42PubMedCrossRef
20.
go back to reference Tan RK, Finley RK 3rd, Driscoll D et al. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995;17:41–7PubMedCrossRef Tan RK, Finley RK 3rd, Driscoll D et al. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995;17:41–7PubMedCrossRef
21.
go back to reference Hadar T, Mor C, Shvero J et al. Anaplastic carcinoma of the thyroid. Eur J Surg Oncol 1993;19:511–6PubMed Hadar T, Mor C, Shvero J et al. Anaplastic carcinoma of the thyroid. Eur J Surg Oncol 1993;19:511–6PubMed
22.
go back to reference Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998;8:715–26PubMedCrossRef Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998;8:715–26PubMedCrossRef
23.
go back to reference Venkatesh YS, Ordonez NG, Schultz PN et al. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990;66:321–30PubMedCrossRef Venkatesh YS, Ordonez NG, Schultz PN et al. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990;66:321–30PubMedCrossRef
24.
go back to reference Sugitani I, Kasai N, Fujimoto Y et al. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 2001;25:617–22PubMedCrossRef Sugitani I, Kasai N, Fujimoto Y et al. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 2001;25:617–22PubMedCrossRef
25.
go back to reference Sugino K, Ito K, Mimura T et al. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 2002;131:245–8PubMedCrossRef Sugino K, Ito K, Mimura T et al. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 2002;131:245–8PubMedCrossRef
26.
go back to reference Pierie JP, Muzikansky A, Gaz RD et al. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 2002;9:57–64PubMedCrossRef Pierie JP, Muzikansky A, Gaz RD et al. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 2002;9:57–64PubMedCrossRef
27.
go back to reference Shimaoka K, Schoenfeld DA, DeWys WD et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155–60PubMedCrossRef Shimaoka K, Schoenfeld DA, DeWys WD et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155–60PubMedCrossRef
28.
go back to reference Asakawa H, Kobayashi T, Komoike Y et al. Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res 1997;17:2757–62PubMed Asakawa H, Kobayashi T, Komoike Y et al. Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res 1997;17:2757–62PubMed
29.
go back to reference Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986;70:405–7PubMed Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986;70:405–7PubMed
30.
go back to reference Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000;10:587–94PubMedCrossRef Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000;10:587–94PubMedCrossRef
31.
go back to reference Schiff BA, McMurphy AB, Jasser SA et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 2004;10:8594–602PubMedCrossRef Schiff BA, McMurphy AB, Jasser SA et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 2004;10:8594–602PubMedCrossRef
32.
go back to reference Straight AM, Oakley K, Moores R et al. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother Pharmacol 2006;57:7–14PubMedCrossRef Straight AM, Oakley K, Moores R et al. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother Pharmacol 2006;57:7–14PubMedCrossRef
Metadata
Title
Treatment Outcomes in Anaplastic Thyroid Carcinoma: Survival Improvement in Young Patients With Localized Disease Treated by Combination of Surgery and Radiotherapy
Authors
Thomas Yau, MBBS
C. Y. Lo, MS
R. J. Epstein, MD
A. K. Y. Lam, MD, PhD
K. Y. Wan, MBBS
Brian H. Lang, MS
Publication date
01-09-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 9/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0005-0

Other articles of this Issue 9/2008

Annals of Surgical Oncology 9/2008 Go to the issue